Corixa Receives Grant To Develop Tuberculosis Vaccine

Corixa Corporation has been awarded a $2.3 million Challenge Grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop a new candidate vaccine for the treatment of tuberculosis. As a result, Corixa will conduct preclinical and clinical testing of a new candidate vaccine produced using M. tuberculosis proteins, combined with formulations developed Read more about Corixa Receives Grant To Develop Tuberculosis Vaccine[…]

Positive Results For InKine’s Cbp-1011 In Patients With Crohn’s Disease

InKine Pharmaceutical Company announced positive results of its multicenter open-labeled, clinical trial of CBP-1011 in the treatment of patients with mild or moderate Crohn’s disease. Key results of the study included* 80% of patients who completed the study responded to treatment with CBP-1011 using endpoints that were previously defined by the U.S. Food and Drug Read more about Positive Results For InKine’s Cbp-1011 In Patients With Crohn’s Disease[…]

Eli Lilly And Reliant Announce Sales And Marketing Agreement

Reliant Pharmaceuticals, LLC, and Eli Lilly and Company announced that Lilly would sell to Reliant the sales and marketing rights for the antiulcer agent Axid in the United States (excluding Puerto Rico). This agreement will help maximize future sales of Axid through expanded sales and marketing efforts and the development of additional formulations by Reliant. Read more about Eli Lilly And Reliant Announce Sales And Marketing Agreement[…]

Squibb Receives Approval For Glucovance

Bristol-Myers Squibb Company has announced U.S. FDA has approved Glucovance (Glyburide and Metformin HCl Tablets) for use, along with diet and exercise, as initial drug therapy for people with type 2 diabetes. The drug was also approved as second-line therapy for patients with type 2 diabetes who are currently taking either or a sulfonylurea and Read more about Squibb Receives Approval For Glucovance[…]

Guilford And Gliatech To Merge

Guilford Pharmaceuticals Inc. and Gliatech Inc. have entered into a definitive merger agreement pursuant to which Guilford will acquire all of the outstanding common stock of Gliatech. The transaction combines the capabilities of both companies in biopolymer development and the development of novel drugs for the treatment of central nervous system disorders. The combined company Read more about Guilford And Gliatech To Merge[…]

Alzheimer’s Treatment Granted FDA Approval

The U.S. FDA has granted Novartis Pharmaceuticals Corporation marketing clearance for Exelon (rivastigmine tartrate) capsules, a cholinesterase inhibitor for the treatment of mild to moderate Alzheimer’s disease. Exelon therapy is proven effective in multiple phase III trials in the three key domains used to assess the disease — global functioning (including activities of daily living Read more about Alzheimer’s Treatment Granted FDA Approval[…]

Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer

Progenics Pharmaceuticals, Inc. and Cytogen Corporation have announced new findings on immune therapies which may play a future role in the treatment of prostate and other cancers. The therapies are directed against Prostate Specific Membrane Antigen (PSMA), a molecular cancer marker that is abundantly expressed on the surface of prostate cancer cells. The developments, presented Read more about Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer[…]

Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration

CuraGen Corporation, an integrated genomics based drug discovery and development company, and Gemini Genomics plc, announced today the largest collaboration to date linking cSNPs (human genetic variations) and clinical information to identify and validate novel drug targets for use in the discovery and development of pharmaceutical and diagnostic products. Specifically, CuraGen and Gemini scientists will Read more about Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration[…]

Nutraceutix Licenses Subsidiary Of Boehringer-ingelheim To Market Calcium D-glucarate

Nutraceutix, Inc. has licensed Quest Vitamins, a subsidiary of Boehringer-Ingelheim, (Canada) Ltd. the non-exclusive right to distribute health supplement products containing the patented dietary supplement compound, Calcium D-Glucarate(TM). Boehringer Ingelheim group, is one of the world’s 20 leading pharmaceutical corporations — with products focused on human pharmaceuticals (prescription, hospital and self-medication) as well as animal Read more about Nutraceutix Licenses Subsidiary Of Boehringer-ingelheim To Market Calcium D-glucarate[…]

Bio-technology General Enters Strategic Alliance

Bio-Technology General Corp. has announced a major, wide-ranging alliance with Al-Kindi Pharmaceutical Industries, a Jordanian company based in Amman, for the distribution of BTG’s pharmaceutical products throughout the Arab world. Under the terms of the agreement, Al-Kindi has exclusive rights to market BTG’s Bio-Hep-B recombinant hepatitis-B vaccine in Jordan, and BTG’s Bio-Tropin recombinant human growth Read more about Bio-technology General Enters Strategic Alliance[…]